Why Don't We Have Proven Treatments for HFpEF?
Why Don't We Have Proven Treatments for HFpEF?
复制标题
DOI：
10.1161/circresaha.116.310119
复制
发表时间：
2017-04-14
影响因子：
20.1
通讯作者：
Rosenzweig A
中科院分区：
文献类型：
--
作者：
Roh J;Houstis N;Rosenzweig A
缺乏有效的治疗心力衰竭保留射血分数(HFpEF)是当今心脏病学中一个巨大且不断增长的未得到满足的需求。HFpEF治疗创新的一个关键障碍是缺乏准确概括人类疾病复杂性的动物模型。在这里，我们提出，如果我们要最大限度地发现和验证HFpEF有效治疗开发的新靶点，更全面的多器官系统和临床前模型的功能表型是必不可少的。
The lack of effective treatments for heart failure with preserved ejection fraction (HFpEF) represents a large and growing unmet need in cardiology today. A critical obstacle to therapeutic innovation in HFpEF has been the absence of animal models that accurately recapitulate the complexities of the human disease. Here we propose that more comprehensive multi-organ system and functional phenotyping of preclinical models is essential if we are to maximize our chances of discovering and validating novel targets for effective therapeutic development in HFpEF.